Trillium Therapeutics

-$0.00 (-0.08%) As of 6:49 PM UTC today

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell TRIL and other ETFs, options, and stocks.

About TRIL

Trillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. It offers clinical programs, TTI-621 and TTI-622, target CD47, a signal that cancer cells frequently use to evade the immune system.

CEO
Jan Skvarka
Employees
—
Headquarters
Mississauga, Ontario
Founded
2004

TRIL Key Statistics

Market Cap
1.01B
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
909.15K
High Today
$6.65
Low Today
$6.43
Open Price
$6.49
Volume
658.27K
52 Week High
$20.96
52 Week Low
$6.35

TRIL Earnings

-$1.07
-$0.22
$0.64
$1.49
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Q1 FY21
Q2 FY21
Estimated
— per share
Actual
Expected Aug 16, After Hours
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure